House Floor Summary

The Speaker announced that the House do now recess. The next meeting is subject to the call of the Chair.

On approving the Journal Agreed to by recorded vote: 216 - 192, 2 Present (Roll no. 122).

On passage Passed by recorded vote: 267 - 149 (Roll no. 121).

On motion to recommit with instructions Failed by the Yeas and Nays: 182 - 233 (Roll no. 120).

Mr. Gowdy asked unanimous consent to take from the Speaker's Table and agree to the Senate amendment.

Motion to reconsider laid on the table Agreed to without objection.

On motion that the House agree to the Senate amendment Agreed to without objection.

ONE MINUTE SPEECHES - The House proceeded with further one minute speeches.

Mr. Gowdy asked unanimous consent that when the House adjourns today, it adjourn to meet at 9:00 a.m. on March 22. Agreed to without objection.

UNFINISHED BUSINESS - The Chair announced that the unfinished business was on the Speaker's approval of the Journal and put the question de novo.

Motion to reconsider laid on the table Agreed to without objection.

The House received a message from the Clerk. Pursuant to the permission granted in Clause 2(h) of Rule II of the Rules of the U.S. House of Representatives, the Clerk notified the House that she received the following message from the Secretary of the Senate on March 21, 2018, at 5:15 p.m.: that the Senate passed H.R. 1865 without amendment.

Considered as unfinished business. H.R. 5247 — "To authorize the use of eligible investigational drugs by eligible patients who have been diagnosed with a stage of a disease or condition in which there is reasonable likelihood that death will occur within a matter of months, or with another eligible illness, and for other purposes."

The House convened, returning from a recess continuing the legislative day of March 21.

POSTPONED PROCEEDINGS - At the conclusion of debate on the Pallone motion to recommit with instructions, the Chair put the question on the motion and by voice vote announced that the ayes had prevailed. Mr. Pallone demanded the yeas and nays, and the Chair postponed further proceedings on the motion to recommit until later in the legislative day.

The Speaker announced that the House do now recess. The next meeting is subject to the call of the Chair.

The previous question on the motion to recommit with instructions was ordered without objection.

DEBATE - The House proceeded with 10 minutes of debate on the Pallone motion to recommit with instructions. The instructions contained in the motion seek to report the same back to the House forthwith with an amendment to require the Food and Drug Administration (FDA) to issue guidance describing how the agency will use expanded access outcomes when considering and evaluating investigational products for full approval. Additionally, the motion seeks to provide liability protection to manufacturers, physicians, and hospitals offering a product under expanded access, as long as the entity is in compliance with current federal law, and it also increases transparency in the FDAs expanded access program.

Mr. Pallone moved to recommit with instructions to the Committee on Energy and Commerce.

The previous question was ordered pursuant to the rule.